These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36908162)
1. Flecainide in clinical practice. Basza M; Maciejewski C; Bojanowicz W; Balsam P; Grabowski M; Mitkowski P; Kempa M; Kowalski O; Kalarus Z; Jaguszewski M; Lubiński A; Daniłowicz-Szymanowicz L; Szumowski Ł; Sterliński M; Kołtowski Ł Cardiol J; 2023; 30(3):473-482. PubMed ID: 36908162 [TBL] [Abstract][Full Text] [Related]
2. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Chimienti M; Cullen MT; Casadei G Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031 [TBL] [Abstract][Full Text] [Related]
3. Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Apostolakis S; Oeff M; Tebbe U; Fabritz L; Breithardt G; Kirchhof P Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160 [TBL] [Abstract][Full Text] [Related]
4. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395 [TBL] [Abstract][Full Text] [Related]
5. Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. Przybylski R; Eberly LM; Alexander ME; Bezzerides VJ; DeWitt ES; Dionne A; Mah DY; Triedman JK; Walsh EP; O'Leary ET J Cardiovasc Electrophysiol; 2023 Dec; 34(12):2545-2551. PubMed ID: 37846208 [TBL] [Abstract][Full Text] [Related]
6. [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder]. Rienstra M; Wiesfeld AC; van Veldhuisen DJ; van Gelder IC Ned Tijdschr Geneeskd; 2006 May; 150(18):1027-31. PubMed ID: 16715868 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia. Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636 [TBL] [Abstract][Full Text] [Related]
8. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. Luedtke SA; Kuhn RJ; McCaffrey FM Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691 [TBL] [Abstract][Full Text] [Related]
9. Using the right drug: a treatment algorithm for regular supraventricular tachycardias. Lévy S; Ricard P Eur Heart J; 1997 May; 18 Suppl C():C27-32. PubMed ID: 9152672 [TBL] [Abstract][Full Text] [Related]
10. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators. Chimienti M; Cullen MT; Casadei G Am J Cardiol; 1996 Jan; 77(3):60A-75A. PubMed ID: 8607393 [TBL] [Abstract][Full Text] [Related]
11. Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting. Kovacs B; Yakupoglu HY; Eriksson U; Krasniqi N; Duru F Cardiol J; 2023; 30(1):82-90. PubMed ID: 36510792 [TBL] [Abstract][Full Text] [Related]
13. The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation. Capucci A; Villani GQ; Piepoli MF; Aschieri D Curr Opin Cardiol; 1999 Jan; 14(1):4-8. PubMed ID: 9932201 [TBL] [Abstract][Full Text] [Related]
14. [Supraventricular tachycardia with wide QRS complexes during Vaughan-Williams class I anti-arrhythmic treatment. Diagnostic and therapeutic implications]. Aouate P; Frank R; Fontaine G; Tonet J; Tageddine R; Benassar A; Turlure A; Jacquemin M; Laborde JP Arch Mal Coeur Vaiss; 1995 Dec; 88(12):1869-74. PubMed ID: 8729368 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Aliot E; Denjoy I Am J Cardiol; 1996 Jan; 77(3):66A-71A. PubMed ID: 8607394 [TBL] [Abstract][Full Text] [Related]
16. The clinical use of class IC antiarrhythmic drugs. Abi Samra F J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646 [TBL] [Abstract][Full Text] [Related]
17. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group. Fish FA; Gillette PC; Benson DW J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902 [TBL] [Abstract][Full Text] [Related]
18. Proarrhythmic effects of class Ic drugs. Moroe K; Annoura M; Matsuo K; Yamanouchi Y; Kumagai K; Arakawa K Clin Ther; 1993; 15(3):559-66. PubMed ID: 8364947 [TBL] [Abstract][Full Text] [Related]
19. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic management of supraventricular tachycardias in children. Part 1: Wolff-Parkinson-White and atrioventricular nodal reentry. Luedtke SA; Kuhn RJ; McCaffrey FM Ann Pharmacother; 1997 Oct; 31(10):1227-43. PubMed ID: 9337449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]